Irvine Pharmaceutical Services has plans to significantly increase capacity over the course of this fiscal year that will double capacity for filling (both lyophilized and liquid), formulation, and biopharmaceutical development by 2Q14.      As part of this initiative, the company incorporated its Avrio parenteral manufacturing facility into the Irvine brand in January. Irvine has since increased technical staff across most departments and plans to add an additional 40 employees during the next ...